These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 27064689)
21. [Changes in diagnostic criteria of thrombotic microangiopathy after stem cell transplantation]. Horváth O; Prohászka Z; Kállay K; Kassa C; Stréhn A; Csordás K; Sinkó J; Kriván G Orv Hetil; 2017 Jul; 158(27):1043-1050. PubMed ID: 28670985 [TBL] [Abstract][Full Text] [Related]
22. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. Skoczynska M; Crowther MA; Chowaniec M; Ponikowska M; Chaturvedi S; Legault K Lupus; 2020 May; 29(6):631-639. PubMed ID: 32252584 [No Abstract] [Full Text] [Related]
23. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840 [TBL] [Abstract][Full Text] [Related]
24. Thrombotic Microangiopathy in Cancer. Weitz IC Semin Thromb Hemost; 2019 Jun; 45(4):348-353. PubMed ID: 31041804 [TBL] [Abstract][Full Text] [Related]
25. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. Shochet L; Kanellis J; Simpson I; Ta J; Mulley W Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT. Peyre M; Sicre de Fontbrune F; Berceanu A; Benjemia L; Castelle M; D'Aveni M; Marçais A; Kaphan E; Bulabois CE; Sirvent A; Rohrlich PS; Coiteux V; Chantepie S; Nguyen-Quoc S; Peffault de Latour R; Coppo P Bone Marrow Transplant; 2024 Jul; 59(7):1034-1036. PubMed ID: 38605146 [No Abstract] [Full Text] [Related]
31. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA. Jodele S; Dandoy CE; Aguayo-Hiraldo P; Lane A; Teusink-Cross A; Sabulski A; Mizuno K; Laskin BL; Freedman J; Davies SM Blood; 2024 Mar; 143(12):1112-1123. PubMed ID: 37946262 [TBL] [Abstract][Full Text] [Related]
32. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332 [TBL] [Abstract][Full Text] [Related]
33. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Bhutani D; Assal A; Mapara MY; Prinzing S; Lentzsch S Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e155-e157. PubMed ID: 32098724 [No Abstract] [Full Text] [Related]
35. Considerations for the Role of the Pharmacist in Managing Patients on Eculizumab for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Denson A; Croom Taylor M; Arnall J Ann Pharmacother; 2023 May; 57(5):622-624. PubMed ID: 36062453 [No Abstract] [Full Text] [Related]
36. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Mizuno K; Dandoy CE; Teusink-Cross A; Davies SM; Vinks AA; Jodele S Blood Adv; 2022 Mar; 6(5):1454-1463. PubMed ID: 35008105 [TBL] [Abstract][Full Text] [Related]
37. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report. Bjørkto MH; Barratt-Due A; Nordøy I; Dörje C; Galteland E; Lind A; Hilli A; Aukrust P; Mjøen G BMC Infect Dis; 2021 Feb; 21(1):137. PubMed ID: 33526010 [TBL] [Abstract][Full Text] [Related]
38. The alternative pathway of complement and the thrombotic microangiopathies. Teoh CW; Riedl M; Licht C Transfus Apher Sci; 2016 Apr; 54(2):220-31. PubMed ID: 27160864 [TBL] [Abstract][Full Text] [Related]
39. Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report. Jarmoliński T; Rosa M; Puziewicz-Zmonarska A; Kałwak K Transplant Proc; 2020 Oct; 52(8):2544-2547. PubMed ID: 32917392 [TBL] [Abstract][Full Text] [Related]
40. Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection. Xu C; Wong V; Kurniawan A; Wilson S; Gopal B; Lawton PD Intern Med J; 2023 Aug; 53(8):1506-1508. PubMed ID: 37599228 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]